SAN DIEGO--(BUSINESS WIRE)--Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.

圣地亚哥--（商业新闻短讯）--Vividion Therapeutics，Inc.，一家生物制药公司，利用新的发现技术，通过精确治疗破坏性癌症和免疫疾病，解锁高价值，传统上不可药用的目标，今天在Nature上宣布了一份里程碑式的出版物。

The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, published jointly with our partner Roche, speaks to the chemical proteomic-enabled discovery of a clinical-stage, covalent allosteric inhibitor of Werner helicase (WRN), VVD-133214 (RO7589831), and further confirms Vividion’s approach to discovering and developing novel therapeutics..

Kristen Baltgalvis等人与我们的合作伙伴Roche联合出版的出版物“WRN解旋酶共价变构抑制剂的化学蛋白质组学发现”，谈到了化学蛋白质组学能够发现临床阶段的Werner解旋酶共价变构抑制剂（WRN），VVD-133214（RO7589831），并进一步证实了Vividion发现和开发新疗法的方法。。

“Vividion discovered covalent ligands targeting a novel allosteric pocket on WRN, a well- known but challenging therapeutic target in drug development. The discovery of this allosteric pocket, early ligands and the lead series were directly enabled by Vividion’s innovative approach to drug discovery, including our chemoproteomics platform and unique covalent fragment library,” said Matt Patricelli, Ph.D., Chief Scientific Officer of Vividion..

Vividion首席科学官Matt Patricelli博士说：“Vividion在WRN上发现了靶向新型变构口袋的共价配体，WRN是药物开发中众所周知但具有挑战性的治疗靶点。这种变构口袋，早期配体和铅系列的发现直接得益于Vividion创新的药物发现方法，包括我们的化学蛋白质组学平台和独特的共价片段库。”。。

WRN is a highly sought after synthetic lethal target for cancers with microsatellite instability (MSI), a genetic state resulting from mutations in DNA damage response pathway genes. MSI is most common in colorectal, endometrial and stomach cancers. The WRN molecule was identified under the collaboration agreement entered between Vividion and Roche in 2020.

WRN是具有微卫星不稳定性（MSI）的癌症的备受追捧的合成致死靶标，微卫星不稳定性是由DNA损伤反应途径基因突变引起的遗传状态。MSI在结直肠癌，子宫内膜癌和胃癌中最常见。WRN分子是根据Vividion和Roche于2020年签订的合作协议确定的。

Roche is currently investigating VVD-133214, also known as RO7589831, in a Phase 1 clinical trial (NCT06004245)..

罗氏目前正在一期临床试验（NCT06004245）中研究VVD-133214，也称为RO7589831。。

“It has been a privilege partnering with Vividion on this significant oncology target, harnessing their leading platform capabilities, and successfully progressing an exceptional molecule into clinical trials within three years from its inception,” said Chris Claiborne, Ph.D., Head, Small Molecule Research and Head of Cancer Cell Targeted Therapy, Roche pharma Research and Early Development (pRED)..

罗氏制药研究与早期开发（pRED）的小分子研究和癌细胞靶向治疗负责人、博士克里斯·克莱伯恩（ChrisClaiborne）说：“在这一重要的肿瘤学目标上与Vividion合作，利用其领先的平台能力，并在其成立后的三年内成功地将一种特殊的分子推进临床试验，这是一种荣幸。”。。

“The publication of Vividion’s allosteric WRN inhibitor in Nature and being one of the first to the clinic on such a challenging target, highlights the ability of Vividion’s covalent chemoproteomic platform to identify and advance druggable vulnerabilities on historically challenging targets,” said Ben Cravatt, Ph.D., Scientific Founder of Vividion..

Vividion的科学创始人Ben Cravatt博士说：“Vividion的变构WRN抑制剂在自然界中的发表，是第一个在这样一个具有挑战性的目标上进入临床的人之一，突显了Vividion的共价化学蛋白质组学平台能够识别和推进历史上具有挑战性的目标上的药物脆弱性。”。。

About Vividion

关于Vividion

Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG acquired in August 2021, is a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders.

Vividion Therapeutics，Inc.是拜耳公司（Bayer AG）于2021年8月收购的全资独立运营子公司，是一家生物制药公司，利用新的发现技术开发高价值，传统上不可药用的靶点，用于精确治疗毁灭性癌症和免疫紊乱。

The company’s platform has enabled it to identify hundreds of previously unknown functional pockets on well-validated protein targets implicated in a wide range of diseases, while simultaneously identifying compounds from its proprietary covalent chemistry library that interact in a highly selective manner with those pockets.

该公司的平台使其能够在涉及多种疾病的经过充分验证的蛋白质靶标上识别数百个以前未知的功能口袋，同时从其专有的共价化学文库中识别与这些口袋高度选择性相互作用的化合物。

The company is leveraging its proprietary chemoproteomic platform to advance a diversified pipeline of highly selective small molecule therapeutics targeting high value, traditionally undruggable targets in oncology and immunology. For more information, please visit www.vividion.com..

该公司正在利用其专有的化学蛋白质组学平台，推进针对肿瘤学和免疫学中高价值，传统上不可药用靶标的高选择性小分子治疗剂的多样化管道。欲了解更多信息，请访问www.vividion.com。。

About Bayer

拜耳简介

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家全球性企业，在医疗保健和营养等生命科学领域拥有核心竞争力。根据其“人人健康，无人饥饿”的使命，该公司的产品和服务旨在通过支持应对全球人口不断增长和老龄化带来的重大挑战，帮助人们和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros.

拜耳致力于推动可持续发展，并对其业务产生积极影响。与此同时，该集团旨在通过创新和增长来提高其盈利能力和创造价值。拜耳品牌代表着全世界的信任、可靠性和质量。2023财年，该集团雇佣了约10万人，销售额476亿欧元。

R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com..

不含特殊项目的研发费用为58亿欧元。欲了解更多信息，请访问www.bayer.com。。

Find more information at https://pharma.bayer.com/

更多信息，请访问https://pharma.bayer.com/

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Facebook: http://www.facebook.com/bayer

Follow us on Twitter: @BayerPharma

在推特上关注我们：@BayerPharma